Do HMG-CoA reductase inhibitors improve kidney function? The saga continues

被引：9
|
作者：
Campese, Vito M. [1 ]
Ku, Elaine [1 ]
Bigazzi, Roberto [1 ]
Bianchi, Stefano [1 ]
机构：
[1] Univ So Calif, Keck Sch Med, Div Nephrol, Los Angeles, CA 90033 USA
来源：
JOURNAL OF NEPHROLOGY | 2011年 / 24卷 / 05期
关键词：
Chronic kidney disease; Proteinuria; Statins; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; RENAL-FUNCTION; ROSUVASTATIN; ATORVASTATIN; PROGRESSION; DYSLIPIDEMIA; EFFICACY; STATINS; WOMEN;
D O I：
10.5301/jn.5000024
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Several reviews have addressed the role of dyslipidemia in renal injury and the potential renal protective effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Experimental evidence in animals strongly supports the concept that statins may be renal protective. However, data in humans are scanty and contradictory. A recent controlled study using rosuvastatin has cast some doubts on the renal protective effect of this drug. This article reviews the available evidence pro and con the renal protective effects of statins in human subjects.
引用
收藏
页码：550 / 553
页数：4
相关论文
共 50 条
  • [21] HMG-CoA reductase inhibitors and the risk of vertebral fracture
    Schoofs, MWCJ
    Sturkenboom, MCJM
    van der Klift, M
    Hofman, A
    AP Pols, H
    Stricker, BHC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (09) : 1525 - 1530
  • [22] HMG-CoA Reductase Inhibitors for Traumatic Brain Injury
    Katlowitz, Kalman
    Gopinath, Shankar
    Cruz Navarro, Jovany
    Robertson, Claudia
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1538 - 1545
  • [23] Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors
    Samizo, Shigeyoshi
    Kaneko, Hiromasa
    ACS OMEGA, 2023, 8 (30): : 27247 - 27255
  • [24] HMG-CoA Reductase Inhibitors as Drug Leads against Naegleria fowleri
    Hahn, Hye Jee
    Abagyan, Ruben
    Podust, Larissa M.
    Roy, Shantanu
    Ali, Ibne Karim M.
    Debnath, Anjan
    ACS CHEMICAL NEUROSCIENCE, 2020, 11 (19): : 3089 - 3096
  • [25] Comparative Tolerability of the HMG-CoA Reductase Inhibitors
    John A. Farmer
    Guillermo Torre-Amione
    Drug Safety, 2000, 23 : 197 - 213
  • [26] The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
    Seyed Soheil Saeedi Saravi
    Seyed Sobhan Saeedi Saravi
    Alireza Arefidoust
    Ahmad Reza Dehpour
    Metabolic Brain Disease, 2017, 32 : 949 - 965
  • [27] Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
    Cho, Yongin
    Choe, EunYeong
    Lee, Yong-ho
    Seo, Ji Won
    Choi, Younjeong
    Yun, Yujung
    Wang, Hye Jin
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (04): : 482 - 488
  • [28] HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis
    Mermis, Joel D.
    Simpson, Steven Q.
    CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (05) : 484 - 492
  • [29] The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
    Saravi, Seyed Soheil Saeedi
    Saravi, Seyed Sobhan Saeedi
    Arefidoust, Alireza
    Dehpour, Ahmad Reza
    METABOLIC BRAIN DISEASE, 2017, 32 (04) : 949 - 965
  • [30] MTD-CoMSIA modelling of HMG-CoA reductase inhibitors
    Duda-Seiman, Daniel M.
    Avram, Speranta
    Mancas, Silvia
    Careja, Valentin
    Duda-Seiman, Corina
    Putz, Mihai V.
    Ciubotariu, Dan
    JOURNAL OF THE SERBIAN CHEMICAL SOCIETY, 2011, 76 (01) : 85 - 99
12345